The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. Export

@article{citeulike:6091102, abstract = {Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists not only improve metabolic abnormalities of diabetes and consequent diabetic nephropathy, but they also protect against nondiabetic chronic kidney disease in experimental models. Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence. Increased local expression of PPAR-gamma paralleled these changes. Underlying mechanisms included increased expression of klotho, decreased systemic and renal oxidative stress, and decreased mitochondrial injury. Pioglitazone also regulated p66(Shc) phosphorylation, which integrates many signaling pathways that affect mitochondrial function and longevity, by reducing protein kinase C-beta. These results suggest that PPAR-gamma agonists may benefit aging-related renal injury by improving mitochondrial function.}, author = {Yang, Hai-Chun C. and Deleuze, Sebastien and Zuo, Yiqin and Potthoff, Sebastian A. and Ma, Li-Jun J. and Fogo, Agnes B.}, citeulike-article-id = {6091102}, citeulike-linkout-0 = {http://dx.doi.org/10.1681/ASN.2008111138}, citeulike-linkout-1 = {http://jasn.asnjournals.org/cgi/content/abstract/20/11/2380}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/19797472}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=19797472}, day = {1}, doi = {10.1681/ASN.2008111138}, issn = {1533-3450}, journal = {Journal of the American Society of Nephrology : JASN}, keywords = {aging, kidney, pparg, rat, shc}, month = {November}, number = {11}, pages = {2380--2388}, posted-at = {2009-11-10 02:35:55}, priority = {2}, title = {The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.}, url = {http://dx.doi.org/10.1681/ASN.2008111138}, volume = {20}, year = {2009} }

TY - JOUR ID - citeulike:6091102 L3 - citeulike-article-id:6091102 N2 - Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists not only improve metabolic abnormalities of diabetes and consequent diabetic nephropathy, but they also protect against nondiabetic chronic kidney disease in experimental models. Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence. Increased local expression of PPAR-gamma paralleled these changes. Underlying mechanisms included increased expression of klotho, decreased systemic and renal oxidative stress, and decreased mitochondrial injury. Pioglitazone also regulated p66(Shc) phosphorylation, which integrates many signaling pathways that affect mitochondrial function and longevity, by reducing protein kinase C-beta. These results suggest that PPAR-gamma agonists may benefit aging-related renal injury by improving mitochondrial function. IS - 11 JF - Journal of the American Society of Nephrology : JASN SN - 1533-3450 EP - 2388 TI - The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. VL - 20 SP - 2380 KW - aging KW - kidney KW - pparg KW - rat KW - shc AU - Yang, Hai-Chun AU - Deleuze, Sebastien AU - Zuo, Yiqin AU - Potthoff, Sebastian AU - Ma, Li-Jun AU - Fogo, Agnes PY - 2009/11/01/ UR - http://dx.doi.org/10.1681/ASN.2008111138 ER -